156 related articles for article (PubMed ID: 23379885)
1. Massive intrafollicular and arterial hyalinosis of the spleen following rituximab and methylprednisolone therapy in a patient with splenic marginal zone lymphoma.
Schaefer IM; Marx A; Sauer C; Hohloch K; Ghadimi BM; Trümper L; Ströbel P
Histopathology; 2013 Mar; 62(4):664-7. PubMed ID: 23379885
[No Abstract] [Full Text] [Related]
2. Comparative outcomes of rituximab-based systemic therapy and splenectomy in splenic marginal zone lymphoma.
Olszewski AJ; Ali S
Ann Hematol; 2014 Mar; 93(3):449-58. PubMed ID: 24057925
[TBL] [Abstract][Full Text] [Related]
3. Treatment of splenic marginal zone lymphoma with rituximab monotherapy: progress report and comparison with splenectomy.
Kalpadakis C; Pangalis GA; Angelopoulou MK; Sachanas S; Kontopidou FN; Yiakoumis X; Kokoris SI; Dimitriadou EM; Dimopoulou MN; Moschogiannis M; Korkolopoulou P; Kyrtsonis MC; Siakantaris MP; Papadaki T; Tsaftaridis P; Plata E; Papadaki HE; Vassilakopoulos TP
Oncologist; 2013; 18(2):190-7. PubMed ID: 23345547
[TBL] [Abstract][Full Text] [Related]
4. Rituximab, used alone or in combination, is superior to other treatment modalities in splenic marginal zone lymphoma.
Else M; Marín-Niebla A; de la Cruz F; Batty P; Ríos E; Dearden CE; Catovsky D; Matutes E
Br J Haematol; 2012 Nov; 159(3):322-8. PubMed ID: 23016878
[TBL] [Abstract][Full Text] [Related]
5. No evidence of splenic disease in patients with splenic marginal zone lymphoma undergoing splenectomy for autoimmune hemolytic anemia after monotherapy with rituximab.
Kalpadakis C; Pangalis GA; Sachanas S; Rontogianni D; Korkolopoulou P; Milionis V; Vassilakopoulos TP; Papadaki HA; Angelopoulou MK
Leuk Lymphoma; 2016 Nov; 57(11):2705-8. PubMed ID: 27082039
[No Abstract] [Full Text] [Related]
6. Significant efficacy of 2-chlorodeoxyadenosine{+/-} rituximab in the treatment of splenic marginal zone lymphoma (SMZL): extended follow-up.
Cervetti G; Galimberti S; Pelosini M; Ghio F; Cecconi N; Petrini M
Ann Oncol; 2013 Sep; 24(9):2434-8. PubMed ID: 23712547
[TBL] [Abstract][Full Text] [Related]
7. [Clinicopathologic study of splenic marginal zone B-cell lymphoma].
Zhang YN; Zheng YY; Zhou XG; Zhang SH; Jin Y; Xie JL; Chen SY; Shi Y; Wu LH
Zhonghua Bing Li Xue Za Zhi; 2009 Apr; 38(4):243-7. PubMed ID: 19575895
[TBL] [Abstract][Full Text] [Related]
8. Splenic marginal zone lymphoma with increased prolymphocytes.
Cai J; Qing X
Blood; 2021 Jun; 137(22):3150. PubMed ID: 34081119
[No Abstract] [Full Text] [Related]
9. Rare presentation of secondary cutaneous involvement by splenic marginal zone lymphoma: report of a case and review of the literature.
Cohen JM; Nazarian RM; Ferry JA; Takvorian RW; Carter JB
Am J Dermatopathol; 2015 Jan; 37(1):e1-4. PubMed ID: 25238446
[TBL] [Abstract][Full Text] [Related]
10. Treatment of splenic marginal zone lymphoma: splenectomy versus rituximab.
Bennett M; Schechter GP
Semin Hematol; 2010 Apr; 47(2):143-7. PubMed ID: 20350661
[TBL] [Abstract][Full Text] [Related]
11. Lupus anticoagulant and thrombosis in splenic marginal zone lymphoma.
Gebhart J; Lechner K; Skrabs C; Sliwa T; Müldür E; Ludwig H; Nösslinger T; Vanura K; Stamatopoulos K; Simonitsch-Klupp I; Chott A; Quehenberger P; Mitterbauer-Hohendanner G; Pabinger I; Jäger U; Geissler K
Thromb Res; 2014 Nov; 134(5):980-4. PubMed ID: 25201005
[TBL] [Abstract][Full Text] [Related]
12. Splenic B-cell lymphomas with more than 55% prolymphocytes in blood: evidence for prolymphocytoid transformation.
Hoehn D; Miranda RN; Kanagal-Shamanna R; Lin P; Medeiros LJ
Hum Pathol; 2012 Nov; 43(11):1828-38. PubMed ID: 22520947
[TBL] [Abstract][Full Text] [Related]
13. Rituximab monotherapy for splenic marginal zone lymphoma with villous lymphocytes: report on long-term disease control for two patients with recurrence after splenectomy.
Debiasi M; Hehnemann M; Garicochea B
Sao Paulo Med J; 2010 Dec; 128(6):375-7. PubMed ID: 21308163
[TBL] [Abstract][Full Text] [Related]
14. Splenic marginal zone lymphoma: excellent outcomes in 64 patients treated in the rituximab era.
Starr AG; Caimi PF; Fu P; Massoud MR; Meyerson H; Hsi ED; Mansur DB; Cherian S; Cooper BW; De Lima MJG; Lazarus HM; Gerson SL; Jagadeesh D; Smith MR; Dean RM; Pohlman BL; Hill BT; William BM
Hematology; 2017 Aug; 22(7):405-411. PubMed ID: 28105889
[TBL] [Abstract][Full Text] [Related]
15. Successful treatment with a rituximab-based regimen of a splenic marginal zone lymphoma with villous lymphocytes in a very frail patient on maintenance dialysis.
Niscola P; Palumbo R; Scaramucci L; Tendas A; Cupelli L; Giovannini M; Piccioni D; Dentamaro T; Perrotti AP; de Fabritiis P
Cancer Chemother Pharmacol; 2009 Mar; 63(4):759-60. PubMed ID: 18500519
[No Abstract] [Full Text] [Related]
16. First-line treatment with bendamustine and rituximab, in patients with intermediate-/high-risk splenic marginal zone lymphomas.
Castelli R; Bergamaschini L; Deliliers GL
Med Oncol; 2017 Dec; 35(2):15. PubMed ID: 29288421
[TBL] [Abstract][Full Text] [Related]
17. [Splenic marginal zone lymphoma complicated by cold agglutinin disease].
Ochi K; Yokoyama K; Ohno N; Ota Y; Tojo A
Rinsho Ketsueki; 2017; 58(2):132-137. PubMed ID: 28321090
[TBL] [Abstract][Full Text] [Related]
18. Splenic marginal zone lymphoma: Prognostic factors, role of watch and wait policy, and other therapeutic approaches in the rituximab era.
Perrone S; D'Elia GM; Annechini G; Ferretti A; Tosti ME; Foà R; Pulsoni A
Leuk Res; 2016 May; 44():53-60. PubMed ID: 27030961
[TBL] [Abstract][Full Text] [Related]
19. Severe Protein-Losing Enteropathy Due to an Indolent Splenic Lymphoma: Case Report and Review of the Literature.
Naymagon L; Ward S; Naymagon S; Navada S
Clin Lymphoma Myeloma Leuk; 2019 Apr; 19(4):e165-e168. PubMed ID: 30685184
[No Abstract] [Full Text] [Related]
20. Risk-tailored treatment of splenic marginal zone lymphoma.
Castelli R; Balzarotti M; Salvi E; Simona Rossi R; Lambertenghi Deliliers G; Bergamaschini L; Gidaro A
Anticancer Drugs; 2022 Jan; 33(1):e36-e42. PubMed ID: 34407041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
